Distinguishing mild cognitive impairment from Alzheimer's disease with acrolein metabolites and creatinine in urine

Clinica Chimica Acta

Volumn 441, Issue , 2015, Pages 115-121

  Yoshida, Madoka ^a   Higashi, Kyohei ^a   Kuni, Kyoshiro ^a   Mizoi, Mutsumi ^a   Saiki, Ryotaro ^a   Nakamura, Mizuho ^a   Waragai, Masaaki ^b   Uemura, Kenichi ^b   Toida, Toshihiko ^a   Kashiwagi, Keiko ^c   Igarashi, Kazuei ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Higashimatsudo Hospital   (Japan)

^c CHIBA INSTITUTE OF SCIENCE   (Japan)

Author keywords

3 HPMA; Acrolein glutathione metabolite; Alzheimer's disease; Amino acid conjugated acrolein; Magnetic resonance imaging; Urinary biomarker

Indexed keywords

3 HYDROXYPROPYL MERCAPTURIC ACID; ACETYLCYSTEINE DERIVATIVE; ACROLEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CREATININE; UNCLASSIFIED DRUG; ACETYLCYSTEINE; S-(3-HYDROXYPROPYL)CYSTEINE N-ACETATE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PROTEIN BLOOD LEVEL; TANDEM MASS SPECTROMETRY; URINE LEVEL; ANALOGS AND DERIVATIVES; METABOLISM; MIDDLE AGED; URINE; VERY ELDERLY;

ACETYLCYSTEINE; ACROLEIN; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

EID: 84920910032     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.12.023     Document Type: Article

References (35)

1. Giorgio M., Trinei M., Migliaccio E., Pelicci P.G. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals?. Nat Rev Mol Cell Biol 2007, 8:722-728.
2. Sharmin S., Sakata K., Kashiwagi K., Ueda S., Iwasaki S., Shirahata A., et al. Polyamine cytotoxicity in the presence of bovine serum amine oxidase. Biochem Biophys Res Commun 2001, 282:228-235.
3. Yoshida M., Tomitori H., Machi Y., Hagihara M, Higashi K, Goda H., et al. Acrolein toxicity: Comparison with reactive oxygen species. Biochem Biophys Res Commun 2009, 378:313-318.
4. Uchida K., Kanematsu M., Morimitsu Y., Osawa T., Noguchi N., Niki E. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 1998, 273:16058-16066.
5. Igarashi K., Kashiwagi K. Modulation of cellular function by polyamines. Int J Biochem Cell Biol 2010, 42:39-51.
6. Igarashi K., Kashiwagi K. Protein-conjugated acrolein as a biochemical marker of brain infarction. Mol Nutr Food Res 2011, 55:1332-1341.
7. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
8. Drachman D.A. Aging of the brain, entropy, and Alzheimer disease. Neurology 2006, 67:1340-1352.
9. Fukumoto H., Tennis M., Locascio J.J., Hyman B.T., Growdon J.H., Irizarry M.C. Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch Neurol 2003, 60:958-964.
10. Sobow T., Flirski M., Kloszewska I., Liberski P.P. Plasma levels of Aβ peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 2005, 65:117-124.
11. Roher A.E., Esh C.L., Kokjohn T.A., Castano EM, Van Vickle GD, Kalback WM, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 2009, 5:18-29.
12. Le Bastard N., Leurs J., Blomme W., De Deyn P.P., Engelborghs S. Plasma amyloid-β forms in Alzheimer's disease and non-Alzheimer's disease patients. J Alzheimers Dis 2010, 21:291-301.
13. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000, 57:100-105.
14. Graff-Radford N.R., Crook J.E., Lucas J., Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007, 64:354-362.
15. Lui J.K., Laws S.M., Li Q.X., Villemagne VL, Ames D, Brown B, et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis 2010, 20:1233-1242.
16. Yaffe K., Weston A., Graff-Radford N.R., Satterfield S, Simonsick EM, Younkin SG, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011, 305:261-266.
17. Tomitori H., Usui T., Saeki N., Ueda S, Kase H., Nishimura K., et al. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke 2005, 36:2609-2613.
18. Yoshida M., Mikami T., Higashi K., Saiki R., Mizoi M., Fukuda K., et al. Inverse correlation between stroke and urinary 3-hydroxypropyl mercapturic acid, an acrolein-glutathione metabolite. Clin Chim Acta 2012, 413:753-759.
19. 40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2012, 32:33-41.
20. 42, and protein-conjugated acrolein. Clin Chim Acta 2014, 430:150-155.
21. Waragai M., Okamura N., Furukawa K., Tashiro M., Furumoto S., Funaki Y., et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease. J Neurol Sci 2009, 285:100-108.
22. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
23. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
24. Igarashi K., Ueda S., Yoshida K., Kashiwagi K. Polyamines in renal failure. Amino Acids 2006, 31:477-483.
25. O'Bryant S.E., Waring S.C., Cullum C.M., Hall J., Lacritz L., Massman PJ., et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol 2008, 65:1091-1095.
26. Shinohara Y., Tohgi H., Hirai S., Terashi A., Fukuuchi Y., Yamaguchi T., et al. Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment. Cerebrovasc Dis 2007, 24:202-209.
27. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
28. Hirata Y., Matsuda H., Nemoto K., Ohnishi T., Hirao K., Yamashita F., et al. Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 2005, 382:269-274.
29. Eckert E., Drexler H., Goen T. Determination of six hydroxyalkyl mercapturic acids in human urine using hydrophilic interaction liquid chromatography with tandem mass spectrometry (HILIC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2506-2514.
30. Gao S., Hendrie H.C., Hall K.S., Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998, 55:809-815.
31. Perry T.L., Berry K., Hansen S., Diamond S., Mok C. Regional distribution of amino acids in human brain obtained at autopsy. J Neurochem 1971, 18:513-519.
32. Tomitori H., Nakamura M., Sakamoto A., Terui Y., Yoshida M., Igarashi K., et al. Augmented glutathione synthesis decreases acrolein toxicity. Biochem Biophys Res Commun 2012, 418:110-115.
33. Park M.H., Igarashi K. Polyamines and their metabolites as diagnostic markers of human diseases. Biomol Ther 2013, 21:1-9.
34. Bermejo P., Martin-Aragon S., Benedi J., Susin C., Felici E., Gil P., et al. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Free Radic Res 2008, 42:162-170.
35. Cristalli D.O., Arnal N., Marra F.A., de Alaniz M.J., Marra C.A. Peripheral markers in neurodegenerative patients and their first-degree relatives. J Neurol Sci 2012, 314:48-56.